Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study by Spencer, Katie et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/208026
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
Clinical Investigation
Net Pain Relief After Palliative Radiation
Therapy for Painful Bone Metastases: A Useful
Measure to Reflect Response Duration? A Further
Analysis of the Dutch Bone Metastasis Study
Katie Spencer, FRCR,*,y Galina Velikova, PhD,*,y Ann Henry, PhD,*,y
Paulien Westhoff, MD, PhD,z Pe ter Hall, PhD,x and
Yvette M. van der Linden, PhDk
*Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; yLeeds Cancer
Centre, Leeds NHS Teaching Hospitals Trust, Leeds, Leeds, United Kingdom; zDepartment of
Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; xEdinburgh
Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; and kDepartment of
Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands
Received Mar 19, 2019. Accepted for publication Jul 4, 2019.
Summary
Patients who respond to
palliative radiation therapy
for bone metastases can
expect improved pain for
approximately 50% of their
remaining life. Net pain re-
lief, although rarely reported,
can provide valuable infor-
mation about response dura-
bility. This is particularly
important when assessing
stereotactic radiation therapy
outcomes. Limited trial
follow-up, long intervals be-
tween questionnaires, and
missing data may result in
significant uncertainty. This
Purpose: Pain response rates are equivalent after single 8 Gy and fractionated pallia-
tive radiation therapy for bone metastases. Reirradiation remains more frequent after a
single fraction, although this does not simply reflect pain recurrence. Given the
possible role of stereotactic radiation therapy in providing durable pain control, mea-
sures of durability are required. Net pain relief (NPR), the proportion of remaining life
spent with pain response, may provide this. This study assesses the use of NPR as an
outcome measure after palliative radiation therapy for bone metastases.
Methods and Materials: This is a secondary analysis of data collected in the Dutch
Bone Metastasis Study, a randomized trial comparing palliative radiation therapy
delivered as 8 Gy in a single fraction and 24 Gy in 6 fractions. NPR was assessed
by survival cohorts, treatment regimen, and primary diagnoses. The consequences
of missing data upon the use of NPR in future studies were considered within sensi-
tivity analyses.
Results: Patients whose pain improved after palliative radiation therapy experienced
improvement for 56.6% of their remaining lives. Missing responses in questionnaires
mean the range of uncertainty in NPR is 36.1% to 62.1%. When response beyond re-
irradiation was excluded, NPR after treatments of single-fraction 8 Gy and 24 Gy in 6
fractions was 49.0% and 56.5%, respectively (P Z .004). Differential willingness to
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latter must be minimized and
clearly reported, and its
consequences must be
assessed where net pain re-
lief is considered.
reirradiate may be influencing this outcome. When response beyond reirradiation was
included, this difference was not seen (NPR of 55.4% vs 57.7%, respectively [P Z
.191]).
Conclusions: Patients who responded to conventional radiation therapy experienced
improved pain control for approximately half of their remaining life. NPR may pro-
vide valuable information in assessing pain response durability. Missing data are, how-
ever, inevitable in this population. This must be minimized and the consequences
recognized and reported. Additionally, reirradiation protocols and the frequency and
duration of trial follow-up may have a significant impact upon this outcome, requiring
careful consideration during trial design if NPR is to be used in future studies.  2019
The Author(s). Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Palliative radiation therapy for painful bone metastases,
alongside analgesia, is the standard of care. Multiple
studies have compared different dose fractionation sched-
ules. Response is assessed as the proportion of individuals
gaining an improvement of at least 2 points on a 0 to 10
point numerical rating scale without concurrent increase in
opioids.1 The extent of response is graded as complete pain
response (CR; pain score 0, no analgesia increase), partial
response (PR; reduction of >1 point in pain score, no
analgesia increase), pain progression (PP; increase of >1
point or analgesia increase without improvement of pain
score), or no response (NR). In meta-analyses of random-
ized studies, single-fraction treatment was as effective for
pain control as multifraction courses with response rates of
approximately 60%.2-4
In attempting to quantify response durability, studies
routinely report reirradiation rates in the absence of
difficult-to-collect longitudinal response data. Twenty
percent reirradiation rates are seen after single-fraction
treatment compared with 8% after multiple-fraction regi-
mens.2,5 Reirradiation reflects a composite endpoint,
encompassing pain response, but also perceived treatment
efficacy and willingness to reirradiate.5 On this basis,
reirradiation does not provide a simple representation of
response durability. In addition, variations in data collec-
tion frequency and pain response assessment make com-
parisons between studies challenging. As such, although no
clear dose-response relationship has been demonstrated
using conventional radiation therapy, the suggestion has
remained that a higher biologically effective dose, poten-
tially delivered using stereotactic radiation therapy, might
provide superior levels of pain relief with greater dura-
bility.6-8
International consensus endpoints have increased ho-
mogeneity in bone metastasis trial conduct and reporting.
These recognize the potential of net pain relief (NPR) as a
possible outcome measure to assess response durability.1
NPR after palliative radiation therapy is defined as the
proportion of remaining life for which pain is improved and
was originally reported by Salazar et al in 1986.9 This may
be particularly relevant in studies assessing the role of
stereotactic treatments. NPR reporting, however, remains
rare owing to limitations of data collection and concern
about the influence of subsequent treatments upon NPR (as
raised by the consensus working party). Where reported, it
was approximately 70%,10,11 but these studies have not
specifically assessed the role of NPR as an outcome.
Although the Dutch Bone Metastasis Study (DBMS)
was performed in the late 1990s, the study collected weekly
and subsequently monthly response questionnaires on pain
and quality of life after radiation therapy.5,12 It was a large
and well conducted trial, with significant resources invested
in minimizing missing data and providing a rich source of
longitudinal data. In the current study, we used the DBMS
data to assess the role and added value of NPR. We aimed
to (1) assess NPR by treatment regimen, diagnostic group,
and survival cohorts and (2) carry out sensitivity analyses to
assess the consequences of missing data considering the
impact this may have upon NPR as an outcome measure.
Methods and Materials
The data used in this analysis were collected by the DBMS
group. Details of the study methods have previously been
published5,12; however, a brief summary follows. A total of
1157 cancer patients with pain (2 on 0-10 numerical
rating scale) due to bone metastases from solid tumors were
recruited across The Netherlands between March 1996 and
September 1998. Patients were randomized to receive a
single 8 Gy fraction or 24 Gy in 6 fractions to the painful
site. Baseline pain score, analgesia, information about the
primary tumor, and demographic characteristics were
collected. Individuals were asked to complete weekly
follow-up questionnaires for the first 12 weeks, with
monthly questionnaires thereafter for a maximum of 24
months (a maximum of 34 questionnaires per patient).
Reirradiation data were collected from treating institutes.
Spencer et al. International Journal of Radiation Oncology  Biology  Physics560
The database was updated and closed in December 1998.
Response rates after treatment have previously been re-
ported.12-14
For the present analysis, patients were grouped accord-
ing to their primary tumor into 4 groups: breast cancer,
prostate cancer, lung cancer, and all other diagnoses.
Baseline characteristics were described for the study pop-
ulation. Survival was defined from the start of radiation
therapy. Survival cohorts were identified as individuals
surviving <6 weeks, 6 to 12 weeks, 12 to 24 weeks, 24 to
52 weeks, and >52 weeks. Individuals censored at trial
closure had unknown survival time. Median survival was
calculated using the Kaplan-Meier method.
The patient’s pain response at each questionnaire was
classified using International Consensus endpoints,1 there-
fore, adjusting for changes in opioid intake (PP, NR, PR, or
CR). Each patient’s overall best response was defined.
Unlike in previous reports, only questionnaire responses
after treatment start were considered, rather than those after
randomization. No exclusions were made for individuals
with missing data to ensure the subsequent sensitivity an-
alyses encompassed all individuals. Each questionnaire was
assumed to represent the whole period since treatment or
the prior questionnaire. Given the fluctuating nature of
pain, it was accepted that patients could move between
response states, experiencing initial response, followed by
NR, and subsequent return to response. Adjustment for
analgesia was made, and this allows for the fluctuating
nature of pain an individual may experience while recog-
nizing if this pain improvement was the result of increased
analgesia. NPR was then calculated as the sum of time
spent with pain response divided by the total time repre-
sented by all observed questionnaires (including those
beyond reirradiation) and multiplied by 100 to give a per-
centage (complete questionnaire analysis NPR [cqaNPR]).
Calculation of mean cqaNPR was carried out in the
following cohorts:
 Initial analyses included only individuals with known
survival time who were known to have responded to
treatment. This determines observed NPR in responders.
This was assessed by survival cohort, diagnosis, and
treatment regimen.
 Subsequently, this analysis was reproduced including
patients with known survival time, but who were not
known to have experienced a response to treatment. This
provides overall expected NPR for all patients.
 Those individuals censored at trial closure and known to
have responded were then considered separately because
their response duration beyond trial closure was not
known.
Mean cqaNPR for different treatment regimens was
compared using 2-sided Student’s t test in individuals with
known survival time.
Studies investigating interventions in patients near the end
of life often have significant amounts of missing data.15 This
does not imply poor study design or conduct.16,17 Where
complete case analysis is carried out, however, it must be
recognized that the act of completing a questionnairemay not
be independent of the patient’s health state and thereforemay
result in biased inference.15 Sensitivity analyses were con-
ducted to determine maximum and minimum possible out-
comes accounting for missing data. These analyses were
carried out by survival cohorts, excluding and including
those not known to have responded. This ensures that the
sensitivity analyses represent the full range of possibilities.
Alternative scenarios considered were as follows:
 cqaNPR assumes that response in unobserved question-
naires was as seen in the observed questionnaires (as
detailed earlier). This includes response beyond
reirradiation.
 NPRa: All unobserved questionnaires were assumed to
represent an NR state (worst case estimate).
 NPRb: Unreturned questionnaires were assumed to
represent response (an anticipated overly optimistic
scenario).
 NPRlv: A last-value-carried-forward approach was used
to replace the missing values. In this analysis, an in-
dividual’s last known pain state was assumed to persist
until the next known state or death. NR is assumed before
the first known response after radiation therapy.
Finally, the consequences of excluding all responses
beyond reirradiation were assessed (ie, assuming these
represent response to reirradiation rather than the original
treatment; NPRc). The exclusion of these responses pro-
vides an assessment of response durability in the absence of
reirradiation.
Results
A total of 1147 patients were included in the study cohort
(19,330 questionnaires). Survival time was known in 849
patients (74%) (12,135 questionnaires). The median sur-
vival after radiation therapy was 29.6 weeks (26.3-32.9) in
the whole population (including those alive at trial closure)
and 18.9 weeks (16.9-20.3) in those who died during trial
follow-up. Figure 1 demonstrates the identification of the
study cohort and details of missing data.
The most common diagnoses were breast (39.2%), lung
(24.5%), and prostate (23.2%) cancer. Breast and prostate
cancer were more frequent in the survivors beyond study
closure. Median baseline pain score was 7 with 26.7% of
patients taking strong opiates (World Health Organization
pain ladder step 3 or 4).18 Baseline characteristics are
shown in Table 1.
Complete questionnaire analysis NPR outcomes
Patients responding to radiation therapy with known sur-
vival time had a mean cqaNPR of 56.6% (standard error,
1.34) (n Z 539), including all responses beyond reirra-
diation. cqaNPR was higher in those known to have expe-
rienced a CR compared with PR (70.2% vs 49.9%,
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respectively). cqaNPR appeared higher in those with very
limited survival, namely 66.4% (<6 weeks of survival [nZ
30 patients]) versus 54.4% in long-term survivors (survival
>52 weeks [n Z 160]), although significantly more data
were missing in the short survival cohort, making these
results difficult to interpret (Fig. 2a and 2b). When response
beyond reirradiation was included, no significant difference
was seen in cqaNPR between the 2 treatment regimens
(55.4% [single 8 Gy] vs 57.7% [24 Gy in 6 fractions] in
responders) (PZ .191) (Table 2a and Fig. 3). Patients with
breast or prostate cancer who responded to treatment
experienced higher cqaNPR (59.4%) than those with lung
or other cancers (cqaNPR 52.2%) (Table 3).
In patients alive at study closure who responded to
treatment, cqaNPR was 66.3% higher than in those with
known survival time (56.6%) (Fig. 2a and 2b). The pro-
portion of breast and prostate cancer patients was higher in
those censored at trial closure (85.5% vs 54.2%), poten-
tially contributing to this higher cqaNPR (Table 1).
Missing data and sensitivity analyses
One hundred and three (12.1%) patients had no observed
response assessment after treatment. Median survival of this
group was 7.86 weeks (95% confidence interval, 6.57-11.14).
Table 1 Baseline characteristics of the total and the study
population
Total cohort Final study cohort
n % n %
Total 1147 100 849 100
Age (range), y (32-89) (32-89)
<55 239 20.8 169 19.91
55-64 279 24.3 205 24.15
65-74 402 35.1 300 35.34
>74 227 19.8 175 20.61
Sex
Male 618 53.9 516 60.78
Female 529 46.1 333 39.22
Primary diagnosis
Breast 449 39.2 261 30.74
Prostate 266 23.2 199 23.44
Lung 281 24.5 257 30.27
Other 151 13.2 132 15.55
Treatment arm
6  4 Gy 571 49.8 430 50.65
1  8 Gy 576 50.2 419 49.35
Performance status
WHO 3-4 170 14.8 155 18.26
WHO 2 436 38.0 359 42.29
WHO 0-1 504 43.9 317 37.34
Unknown 37 3.2 18 2.12
Baseline pain score
2 16 1.4 7 0.82
3 40 3.5 29 3.42
4 71 6.2 47 5.54
5 131 11.4 91 10.72
6 125 10.9 87 10.25
7 180 15.7 137 16.14
8 330 28.8 257 30.27
9 134 11.7 104 12.25
10 117 10.2 88 10.37
Unknown 3 0.3 2 0.24
Baseline analgesia
None 145 12.6 86 10.13
Simple 415 36.2 276 32.51
Weak opioids 214 18.7 157 18.49
Strong opioids 306 26.7 273 32.16
Unknown 67 5.8 57 6.71
1,157 randomised patients
 (20,727 questionnaires)
8,375 observed
3,760 missing
(31%)
5,483 observed
1,712 missing
(24%)
746 individuals
(88%) with ≥1
response
observed
283 individuals
(95%) with ≥1
response
observed
Missing:
362 (9.6%)
intermittent
577 (15.3%)
missing baseline
2,821 (75.0%)
prior to death
Missing:
250 (14.6%)
intermittent
235 (13.7%)
missing baseline
1,227 (71.7%)
prior to death
3 patients with no post-
treatment questionnaires and 
total 1,336 pre-treatment
questionnaires excluded
1,147 patients
(19,330 questionnaires)
849 patient with known
survival time
(12,135 questionnaires)
298 patients censored at
trial closure
(7,195 questionnaires)
7 patients (61 questionnaires)
excluded due to unknown
treatment date
1,150 patients
(20,666 questionnaires)
Fig. 1. CONSORT diagram illustrating the study popu-
lation. The 3 patients excluded due to lack of posttreatment
questionnaires died before the first follow-up questionnaire
was completed.
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In the population who were observed until death, 3760
questionnaires were missing (31.0%). Missing data were
more common for patients with limited observed survival
(49.4% missing [<6 weeks]; 26.5% missing [>52 weeks]).
In individuals who returned at least 1 posttreatment ques-
tionnaire, 38.7% of questionnaires were missing in non-
responders whereas 21.6% were missing in responders.
Fewer data were missing after single 8 Gy treatment
(29.58% vs 32.4% [c2d P Z .001]).
The outcomes of sensitivity analyses by survival cohort
are shown in Figure 2c and 2d. The range of possible
outcomes for NPR was 36.1% to 62.1% in responders
(cqaNPR 56.6%) and 22.9% to 59.6% (NPRa-NPRb) in all
patients (cqaNPR 40.9%). NPRlv revealed outcomes be-
tween cqaNPR and the lower limit of sensitivity analyses
(52.8% [responders] and 38.1% [all patients]).
Only 115 individuals (13.5%) with known survival time
returned enough questionnaires to allow assessment of more
than 90% of their remaining life. The median survival of this
group was 33.0 weeks; 101 individuals (87.8%) were re-
sponders, of whom 48 (41.7%) were complete responders
(comparedwith 17.4%CR in thosewith<90% timeobserved).
In responders in this cohort the mean cqaNPR was 55.7%.
In patients with known survival time, reirradiation
occurred in 26.0% in the single 8 Gy arm and 7.9% in the
24 Gy arm. When all questionnaires beyond reirradiation
were assumed to reflect no response, NPRc was greater
after 24 Gy than after 8 Gy (56.5% vs 49.0% in responders
[P Z .004]) (Table 2b and Fig. 3c).
Discussion
Durability of pain control is an important outcome for pa-
tients undergoing palliative radiation therapy for painful
bone metastases.19,20 International consensus endpoints
recommend reporting responding proportion; however, this
method does not provide information on response dura-
bility. Reirradiation rates are used as a proxy for response
duration on the assumption that reirradiation reflects PP
after an initial pain response. This assumption is ques-
tionable when comparing the 2 treatment arms here due to
knowledge that reirradiation is carried out at lower pain
scores more promptly and in greater numbers irrespective
of response status after single 8 Gy treatments compared
with 24 Gy in 6 fractions; it is not purely a measure of
response durability.5 NPR reflects the time spent in
response divided by the actual survival time and has po-
tential to provide this information.
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Fig. 2. Complete questionnaire analysis net pain relief (NPR) in (a) all patients and (b) responders by survival cohort.
Patients censored at trial closure considered separately. Complete questionnaire analysis NPR is shown by the black dot with
sensitivity analyses illustrated by surrounding bars (NPRa-NPRb).
Table 2 Complete questionnaire analysis of net pain relief
by radiation therapy regimen received
Arm % NPR in responders
(a) n Mean (%) Standard error
1  8 Gy 269 55.4 1.95
6  4 Gy 270 57.7 1.84
(b)
1  8 Gy 269 49.0 1.88
6  4 Gy 270 56.5 2.08
(a) Complete questionnaire analysis of net pain relief values
including response beyond re-treatment (P Z .3863); (b) excluding
responses beyond retreatment (P Z .008). Missing questionnaires
accounted for 29.6% and 32.4% in the single 8 Gy and 6  4 Gy
groups, respectively. Re-treatment occurred after 26.0% of single 8 Gy
treatments and 7.9% of 6  4 Gy treatments.
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In this study, patients who responded to palliative radi-
ation therapy gained improved pain control for 56.6% of
their remaining life (cqaNPR). No difference was seen in
cqaNPR after single- and multiple-fraction palliative radi-
ation therapy in responders (55.5% vs 57.5%), although a
significant difference was seen when response beyond
reirradiation was excluded (49.0% vs 56.5% respectively).
Although statistically significant, it is unclear if this latter
difference is of sufficient scale to be clinically relevant
given the recognition that reirradiation is not a simple
reflection of pain; therefore, this outcome is likely to be
confounded by differential willingness to re-treat between
the treatment arms.5
Challenges to NPR as a trial outcome measure
Although appealing in its potential to offer valuable in-
formation about response durability, we demonstrate that
challenges exist in the use of NPR as an outcome measure.
Despite being a well-conducted study, significant
numbers of questionnaire responses are missing, as is
anticipated in studies investigating palliative interventions.15
Complete questionnaire analysis (cqaNPR) assumes that the
proportion of time spent in response in observed question-
naires reflects the proportion in unobserved questionnaires.
This assumption is questionable if patients whose clinical
condition is below average are less likely to return ques-
tionnaires; thatmoremissing data are seen near the end of life
reinforces the likely violation of this assumption. As a
consequence, cqaNPR is likely to represent an optimistic
estimate of true NPR. Those with known survival time and
>90% of their remaining life observed (nZ 115) provide the
greatest certainty in NPR outcomes. In this group, cqaNPR
was 55.9%, although the higher proportion of CR in this
cohort means this too may be an optimistic estimate. Those
who gain a pain response after palliative radiation therapy for
bone metastases can expect improved pain control for
approximately half of their remaining life, with patients with
prostate and breast cancer experiencing better outcomes than
those with other cancers.
By reporting both intention to treat and assessable re-
sponses, existing studies recognize the impact of missing
data (due to death and incomplete data).2,4,21 A range of
possible outcomes can be derived based on the findings of
Chow et al.2 Response in assessable individuals (complete
case analysis) was 72%, with a possible range of 60% to
76.7%. The range of NPR outcomes demonstrated here
(36.1%-62.1%) is greater than that seen in overall response
rates. NPR was similar in the treatment groups considered
here (8 Gy and 24 Gy); however, if interventions with
markedly different outcomes are compared, the potential
for systematic bias due to missingness must be
acknowledged.
NPR, as measured here, recognizes that patients’
symptoms may fluctuate,22 accepting all pain response
beyond first recurrence of pain as reflecting this fluctuation.
Importantly, where response beyond further treatment
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Fig. 3. Net pain relief (NPR) by treatment arms; sensitivity analyses shown in the gray bars with complete questionnaire
analysis NPR the black dot, sensitivity analyses in gray (NPRa-NPRb), (a) All patients, (b) responders, (c) NPRceexcluding
response beyond reirradiation. Individuals censored at trial closure excluded.
Table 3 Complete questionnaire analysis of net pain relief
by primary diagnosis in patients with known survival time (all
patients and those with known pain response considered
separately)
Primary
diagnosis
All patients Responders
n Mean (%)
Standard
error n Mean (%)
Standard
error
Breast 236 46.1 2.42 183 59.4 2.33
Prostate 177 48.6 2.71 145 59.3 2.56
Lung 215 33.3 2.41 134 53.4 2.63
Other 118 32.6 3.18 77 49.9 3.52
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(such as reirradiation) was included, the distinction be-
tween response due to the initial treatment and response
due to subsequent treatment was not made. This is poten-
tially a limitation. It is, however, notable that even where
response beyond reirradiation is excluded, the difference
between the 2 treatment arms is 7.5% of remaining life in
responders. Reirradiation after single 8 Gy treatment was
observed in 26% of patients with a known date of death in
this study (compared with 7.9% after 24 Gy in 6 fractions).
More contemporaneous studies have demonstrated mark-
edly lower reirradiation rates after single 8 Gy treatments
(as low as 14%).23 Given that the decision to reirradiate is
not a simple reflection of pain control, the exclusion of
responses post-reirradiation risks introducing the same bias
as is present when reirradiation itself is used as an end-
point.5 Conversely, inclusion of these responses is ques-
tionable when assessing response durability. Overall, the
proportion of remaining life spent with pain response was
the same for patients receiving these 2 regimens. For a
proportion of patients undergoing single-fraction treatment,
reirradiation may be contributing to this. Notably, 74% of
patients in the single-fraction arm did not require reirra-
diation and were saved a further 5 treatment attendances.
Reporting of NPR, both including and excluding response
beyond reirradiation, may therefore be appropriate. In
addition, future studies should ensure clear protocols to
ensure that the reirradiation endpoint is as unbiased as
possible.23
Patients who responded and were alive at trial closure
experienced higher NPR than those observed until death
(cqaNPR of 66.3% vs 56.6%). It is not possible to deter-
mine whether this difference reflects the nature of the
censored group (greater proportion of breast and prostate
cancer, longer survival times) or the fact that the observa-
tions included were relatively closer to treatment, possibly
not including the point of pain recurrence. With well-
balanced treatment arms, this may not be a problem, but
differing follow-up periods with variable time points for
response assessment will limit comparability of NPR be-
tween studies. This has implications for the use of NPR in
stereotactic radiation therapy studies, as benefit may be
anticipated to be greatest in patients with longer survival
who are more likely to be censored at trial closure.
A further limitation of the NPR outcome is that a
returned questionnaire is assumed to be representative of
the entire period since the previous questionnaire. Ques-
tionnaires, however, focused upon an individual’s worst
pain over the preceding week because robust capture of
experienced pain can only be achieved over short periods in
cancer patients.12,24,25 As such, these outcomes rely upon
the assumption that symptoms remain stable between
questionnaires. Notably, Foro Arnalot et al report NPR of
68%, whereas Salazar et al report NPR of 71%, possibly
reflecting the limited longitudinal data collected.10,11
Longer periods between questionnaires will increase
uncertainty in NPR outcomes.
Implications for the use of NPR in future bone
metastases trials
Unfortunately, missing data during follow-up are inevitable
in this patient population and will remain a limitation of
NPR as an outcome measure, particularly in subgroups
where missing data are more prevalent (eg, those with very
limited prognosis). Caution is required in interpreting out-
comes in these groups. These uncertainties should not,
however, prevent the use of NPR as an outcome measure in
future trials, although they have implications for trial
conduct and reporting:
 Specific efforts, beyond those already in place, are
required to minimize missing data (eg, ensuring com-
plete collection of baseline data, increasing questionnaire
completion, and balancing questionnaire burden with
adequate follow-up).15
 The collection of outcomes using digital platforms has
been shown to be feasible and beneficial in advanced
cancer and might enable capture of weekly outcomes to
reduce uncertainty in the measurement of NPR.26
 The use of cohort multiple randomized controlled trial
designs could be considered to aid recruitment and gain
follow-up information for a cohort receiving standard
treatment. The challenges of this in a population with
limited prognosis may, however, be significant.27,28
 Robust reporting of the extent of missing data and
sensitivity analyses will be required to allow compari-
sons of NPR both within and between trials.29
 Although assessing NPR in all patients (both responders
and nonresponders) provides an important sensitivity
analysis, the increased uncertainty introduced by
including nonresponders can be avoided by assessing this
outcome only in responders. The question answered by
these 2 results differs and given the overall aim of
comparing treatment efficacy, it may be necessary to
accept (and recognize) this uncertainty.
Despite comparable response rates after fractionated and
single-dose treatments for patients with painful bone me-
tastases, the justification offered for fractionated radiation
therapy is often response durability, as measured by reir-
radiation rates.20 Yet reirradiation is not simply a function
of pain recurrence,5 and no measure of durability of pain
control has been routinely reported in studies. In addition, if
we are to make the case for stereotactic radiation therapy
with higher total doses on the basis of durability of pain
control, measures that are able to evaluate this outcome are
required.
NPR might address these concerns; however, given the
inevitability of missing data in palliative care studies, var-
iable frequency of pain assessment, and practicalities of
trial duration, uncertainty in the measurement of NPR is
significant. Consensus guidelines should consider its
incorporation and provide methodological and reporting
recommendations to minimize these limitations. If this can
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be achieved, NPR may provide valuable information within
trial information about an outcome of clear importance to
patients.19,30 Comparison between trials can be improved
by consensus but may remain a limitation.
Conclusions
NPR provides useful additive information next to response
percentages when interpreting outcomes of trials treating
patients with painful bone metastases.
References
1. Chow E, Hoskin P, Mitera G, et al. Update of the international
consensus on palliative radiotherapy endpoints for future clinical trials
in bone metastases. Int J Radiat Oncol Biol Phys 2012;82:1730-1737.
2. Chow E, Zeng L, Salvo N, et al. Update on the systematic review of
palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll
Radiol) 2012;24:112-124.
3. Sze WM, Shelley M, Held I, et al. Palliation of metastatic bone pain:
Single fraction versus multifraction radiotherapy - a systematic review
of the randomised trials. Cochrane Database Syst Rev 2004;
CD004721.
4. Rich SE, Chow R, Raman S, et al. Update of the systematic review of
palliative radiation therapy fractionation for bone metastases. Radio-
ther Oncol 2018;126:547-557.
5. van der Linden YM, Lok JJ, Steenland E, et al. Single fraction
radiotherapy is efficacious: A further analysis of the Dutch Bone
Metastasis Study controlling for the influence of retreatment. Int J
Radiat Oncol Biol Phys 2004;59:528-537.
6. van der Velden JM, Verkooijen HM, Seravalli E, et al. Comparing
conVEntional RadioTherapy with stereotactIC body radiotherapy in
patients with spinAL metastases: Study protocol for an randomized
controlled trial following the cohort multiple randomized controlled
trial design. BMC Cancer 2016;16:909.
7. Braam P, Lambin P, Bussink J. Stereotactic versus conventional
radiotherapy for pain reduction and quality of life in spinal metastases:
Study protocol for a randomized controlled trial. Trials 2016;17:61.
8. Ryu S, Pugh SL, Gerszten PC, et al. RTOG 0631 phase 2/3 study of
image guided stereotactic radiosurgery for localized (1-3) spine me-
tastases: Phase 2 results. Pract Radiat Oncol 2014;4:76-81.
9. Salazar OM, Rubin P, Hendrickson FR, et al. Single-dose half-body
irradiation for palliation of multiple bone metastases from solid tu-
mors. Final Radiation Therapy Oncology Group report. Cancer 1986;
58:29-36.
10. Foro Arnalot P, Fontanals AV, Galcera´n JC, et al. Randomized clinical
trial with two palliative radiotherapy regimens in painful bone me-
tastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction.
Radiother Oncol 2008;89:150-155.
11. Salazar OM, Sandhu T, da Motta NW, et al. Fractionated half-body
irradiation (HBI) for the rapid palliation of widespread, symptom-
atic, metastatic bone disease: A randomized phase III trial of the In-
ternational Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol
Phys 2001;50:765-775.
12. Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single
fraction compared to multiple fractions on painful bone metastases: A
global analysis of the Dutch Bone Metastasis Study. Radiother Oncol
1999;52:101-109.
13. van der Linden YM, Steenland E, van Houwelingen HC, et al. Patients
with a favourable prognosis are equally palliated with single and
multiple fraction radiotherapy: Results on survival in the Dutch Bone
Metastasis Study. Radiother Oncol 2006;78:245-253.
14. Meeuse JJ, van der Linden YM, van Tienhoven G, et al. Efficacy of
radiotherapy for painful bone metastases during the last 12 weeks of
life: Results from the Dutch Bone Metastasis Study. Cancer 2010;116:
2716-2725.
15. Hussain JA, White IR, Langan D, et al. Missing data in randomized
controlled trials testing palliative interventions pose a significant risk
of bias and loss of power: A systematic review and meta-analyses. J
Clin Epidemiol 2016;74:57-65.
16. Currow DC, Plummer JL, Kutner JS, et al. Analyzing phase III studies
in hospice/palliative care. A solution that sits between intention-to-
treat and per protocol analyses: The palliative-modified ITT anal-
ysis. J Pain Symptom Manage 2012;44:595-603.
17. Preston NJ, Fayers P, Walters SJ, et al. Recommendations for man-
aging missing data, attrition and response shift in palliative and end-
of-life care research: Part of the MORECare research method guid-
ance on statistical issues. Palliat Med 2013;27:899-907.
18. World Health Organization. WHO’s cancer pain ladder for adults.
Available at: http://www.who.int/cancer/palliative/painladder/en/.
Accessed May 31, 2017.
19. Hechmati G, Hauber AB, Arellano J, et al. Patients’ preferences for
bone metastases treatments in France, Germany and the United
Kingdom. Support Care Cancer 2015;23:21-28.
20. van der Linden Y, Roos D, Lutz S, et al. International variations in
radiotherapy fractionation for bone metastases: Geographic borders
define practice patterns? Clin Oncol (R Coll Radiol) 2009;21:
655-658.
21. Chow E, van der Linden YM, Roos D, et al. Single versus multiple
fractions of repeat radiation for painful bone metastases: A rando-
mised, controlled, non-inferiority trial. Lancet Oncol 2014;15:
164-171.
22. de Wit R, van Dam F, Hanneman M, et al. Evaluation of the use of a
pain diary in chronic cancer pain patients at home. Pain 1999;79:89-
99.
23. Hoskin P, Rojas A, Fidarova E, et al. IAEA randomised trial of
optimal single dose radiotherapy in the treatment of painful bone
metastases. Radiother Oncol 2015;116:10-14.
24. Shi Q, Trask PC, Wang XS, et al. Does recall period have an effect on
cancer patients’ ratings of the severity of multiple symptoms? J Pain
Symptom Manage 2010;40:191-199.
25. Jensen MP, Wang W, Potts SL, et al. Reliability and validity of indi-
vidual and composite recall pain measures in patients with cancer.
Pain Med 2012;13:1284-1291.
26. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-
reported outcomes during routine cancer treatment: A randomized
controlled trial. J Clin Oncol 2016;34:557-565.
27. van der Velden JM, Verkooijen HM, Young-Afat DA, et al. The cohort
multiple randomized controlled trial design: A valid and efficient
alternative to pragmatic trials? Int J Epidemiol 2017;46:96-102.
28. Relton C, Torgerson D, O’Cathain A, et al. Rethinking pragmatic
randomised controlled trials: Introducing the “cohort multiple rando-
mised controlled trial” design. BMJ 2010;340:c1066.
29. Hussain JA, Bland M, Langan D, et al. Quality of missing data
reporting and handling in palliative care trials demonstrates that
further development of the CONSORT statement is required: A sys-
tematic review. J Clin Epidemiol 2017;88:81-91.
30. Shakespeare TP, Lu JJ, Back MF, et al. Patient preference for radio-
therapy fractionation schedule in the palliation of painful bone me-
tastases. J Clin Oncol 2003;21:2156-2162.
Spencer et al. International Journal of Radiation Oncology  Biology  Physics566
